

Robert Lynn Horne, MD, Ltd

3025 W. Sahara Ave., Suite 200

Las Vegas, NV 89102

Office: (702) 822-1188

Fax: (702) 822-2020

June 7, 2021

Pharmacy and Therapeutics Committee/Silver State Scripts Board
State of Nevada Department of Health and Human Services
Division of Health Care Financing and Policy
1100 E. William Street, Suite 101
Carson City, Nevada 89701

RE: Agenda item 6d – Discussion and possible adoption of Psychotropic Agents – Antipsychotics – Atypical Antipsychotics – Oral

I understand that Silver State Scripts board meeting on June 24, 2021, will review possible adoption of psychotropic Agents – Antipsychotics – Atypical Antipsychotics – Oral drug class review by OptumRX agenda item 6d. I would like to request that the committee add Caplyta at a preferred status on the PDL for schizophrenia.

The process of two drug failures and then prior authorization steers some clinicians away from using medications that may be optimal were it not for this time consuming process which can delay improvement significantly.

Thank you for your consideration.

Sincerely yours,



Robert Lynn Horne, MD
Distinguished Life Fellow, American Psychiatric Association
Diplomate, American Board of Psychiatry and Neurology
Diplomate, American Board of Forensic Medicine
Diplomate, American Academy of Pain Management
Professor of Psychiatry, Roseman University of Health Sciences